Genmab — September 2020

[E_L]

they are also presenting at Citi this week, not sure if we can see anything from that

[E_L]

yes, CD47 is clearly the hot target atm. Genmab better hurry, you 'Blink' and you miss your opportunity

[E_L]

New: Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With R/R B-NHL https://clinicaltrials.gov/ct2/show/NCT04542824?term=NCT04542824&draw=2&rank=1

[Helge_LarsenPI-redaktør]

Join Genmab at #SOHO2020, a virtual event from September 9 to 12, 2020. Visit our virtual booth at http://genmab-at-soho-2020.com to get the latest information about our presentations, antibody platforms and pipeline. Get more info at http://soho2020.com @SocietyofHemOnc

[E_L]

BAML sees Kesimpta in MS $5bn peak sales $5bn

[Solsen]

I like that

[E_L]

If anyone is interested in a position as postdoctoral dara researcher with dr. Niels van Donk

• https://www.academictransfer.com/en/294131/postdoc-cancer-center-amsterdam/

[transalp]

Go morgen..

[Mcjean]

Maybe now E L from Genmabchat will join the adventure and use some of his huge energy in this stock, because now Qfuel arrive to netherland:-D

[E_L]

E L from Genmabchat thinks he missed that -plastic- boat But he says that if he can sell his Genmabs at 18.000 he may look into it again

[Mcjean]

Whole new business my friend, you better join

[Topo]

Jeg skylder sgu dig en øl for dit skriv om qfuel Mcjean

[StockBull]

https://nbg1.your-objectstorage.com/proinvestor-dev/forum/boards/86671_Oct_8_target.JPG mulig kursudvikling kommende måned såfremt markedet opføre sig pænt

[Sukkeralf]

Just a moment...

(www.firstwordpharma.com)

[Sukkeralf]

test

[Sukkeralf]

The study found the addition of NINLARO to lenalidomide and dexamethasone resulted in a 13.5 month increase in median progression-free survival (PFS) (35.3 months in the NINLARO arm, compared to 21.8 months in the placebo arm

[Sukkeralf]

The trial did not meet the threshold for statistical significance and the primary endpoint of PFS was not met.

[E_L]

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

[E_L]

Janssen Submits Application Seeking U.S. FDA Approval of DARZALEX FASPRO™ (daratumumab and hyaluronidase-fihj) for the Treatment of Patients with Light Chain (AL) Amyloidosis

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the submission of a supplemental Biologics License Application (sBLA)...

(www.prnewswire.com)

[E_L]

The sBLA is being reviewed under the FDA Real-Time Oncology Review (RTOR) program,